Nucific review

Nucific is genuinely unusual: it cites the SURMOUNT-1 trial by name with the actual 20.9% figure and the Jastreboff NEJM 2022 reference, labels its NAD⁺ decline chart an illustrative model rather than a measurement, and discloses that the patients in its testimonials were compensated. Most of this category does none of those things. It also puts a number on every treatment card — sermorelin and each of its three NAD⁺ routes are 'as low as $149/month'. What the number does not tell you is the plan length, the dose or what a month at full price costs; those only appear inside the intake.

Nucific is a telehealth service whose homepage names Dr. Amy Lee, MD as founder, described as triple board-certified in internal medicine, obesity medicine and clinical nutrition. Its prescription catalog is compounded semaglutide and tirzepatide (as low as $117 and $139 a month), microdosed versions of both, brand-name Zepbound and Ozempic, and a longevity line of injectable sermorelin, NAD⁺ in three routes — injection, oral liposomal liquid and nasal spray — and a B12 MIC injection. The same site also sells its long-standing nutrition supplements, led by the Bio-X4 probiotic formula, under the Pacific Health Supplements, LLC name, so the brand is both a supplement retailer and a prescription telehealth service.

Quiz-led and asynchronous: a three-minute assessment, same-day approval if eligible, treatment shipped in discreet packaging from what the site calls licensed US pharmacies, and unlimited provider messaging afterwards. The presentation layer is where Nucific separates itself. The weight-loss claim is anchored to a named trial with the average and the citation attached. The NAD⁺ chart — the one every competitor draws without explanation — carries a methodology note stating that the curve is a simplified model, not a measurement of any individual, and that reported values and rates of decline differ across studies, tissues, sexes and measurement methods; the 'in hours, in days' timeline beside it is labeled as commonly reported experience, not trial results. The testimonial block states outright that the people featured were compensated for their time. That is a materially higher standard than the norm. What sits against it is verification: the LegitScript badge is a self-hosted image rather than the issued embed, although it links to LegitScript's checker, and the BBB accreditation badge links to a BBB profile filed under vitamins and supplements in Westlake Village, California. No state list is published and no pharmacy is named.

Every treatment card carries an entry figure. Sermorelin injection, NAD⁺ injection, NAD⁺ nasal spray and NAD⁺ oral liposomal liquid are each 'as low as $149/month', and the B12 MIC injection is 'as low as $109/month'. On the weight-loss side, compounded semaglutide is as low as $117/month, compounded tirzepatide $139, the microdose versions $130 and $150, and brand Ozempic and Zepbound $1,498 and $1,828. The homepage FAQ says there is no membership fee and no hidden costs, and that HSA and FSA dollars can be used. Read 'as low as' literally: the cards do not say whether that figure is a monthly rate, a multi-month prepay rate or a first-order price, and the plans behind it are only shown inside the intake. Before you complete the assessment, ask what one month of sermorelin costs without a commitment, whether the three NAD⁺ routes stay at the same price as the dose changes, and what the cancellation terms are, since none of those is published for the prescription line.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Nucific's catalog mixes compounded preparations, which are not reviewed by the FDA for purity and potency the way approved drugs are, with genuine brand-name Zepbound and Ozempic. The pharmacy is not named. On the evidence, its longevity line is weaker than its GLP-1 line, and to the site's credit its own copy is careful rather than overreaching. Sermorelin is a GHRH analog that signals your own pituitary to release growth hormone rather than supplying it — a real, well-described mechanism, with thin long-term human outcome data behind the sleep, body-composition and healthy-aging claims made for it. NAD⁺ is the harder case: injected, intranasal and sublingual NAD⁺ have no controlled human outcome trials at all, and the oral liposomal route has none either. The NAD⁺ forms with human data are the oral precursors NR and NMN, which reliably raise blood NAD⁺ — a raised biomarker, not a demonstrated clinical benefit — which is precisely why the site's own disclaimer about the decline curve being illustrative is the right call. Its Bio-X4 and probiotic supplements are dietary supplements, not prescription products, and carry the standard note that their claims have not been evaluated by the FDA. Individual results vary.